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ABSTRACT: Ghrelin is a strong physiologic growth hormone secre-
tagogue that exhibits endocrine and non-endocrine actions. In this
study, ghrelin expression in humans and rats was evaluated through-
out development of normal and hypoplastic lungs associated with
congenital diaphragmatic hernia (CDH). Additionally, the effect of
antenatal treatment with ghrelin in the nitrofen-induced CDH rat
model was tested. In normal lungs, ghrelin was expressed in the
primitive epithelium at early stages of development and decreased in
levels of expression with gestational age. In hypoplastic lungs ghrelin
was overexpressed in both human and rat CDH fetuses when com-
pared with controls. Exogenous administration of ghrelin to nitrofen-
treated dams led to an attenuation of pulmonary hypoplasia of CDH
pups. Furthermore, the growth hormone, secretagogue receptor
(GHSR1a), could not be amplified from human or rat fetal lungs by
RT-PCR. In conclusion, of all the lungs studied so far, the fetal lung
is one of the first to express ghrelin during development and might be
considered a new source of circulating fetal ghrelin. Overexpression
of ghrelin in hypoplastic lungs and the effect of exogenous admin-
istration of ghrelin to nitrofen-treated dams strongly suggest a role
for ghrelin in mechanisms involved in attenuation of fetal lung
hypoplasia, most likely through a GHSR1a-independent pathway.
(Pediatr Res 59: 531–537, 2006)
Congenital diaphragmatic hernia (CDH) is a severe anom-aly with a mean incidence of approximately 1 in 2,500
newborns. Despite research and clinical efforts to enhance
treatment, the mortality rate of the most severely affected
subset of CDH infants did not change significantly during the
last decades (1). Lung hypoplasia and pulmonary hypertension
associated with this pathology are the major reasons for the
failure of the currently available treatments. Reversing lung
hypoplasia surgically during the prenatal development has
been attempted; however, this intervention is invasive, tech-
nically demanding and limited by the maternal and fetal risk
(2). Thus, antenatal therapies that promote lung growth remain
an appealing approach for fetuses with severe CDH (3,4).
Ghrelin is an endogenous peptide described as a strong
physiologic growth hormone (GH) secretagogue by interac-
tion with the growth hormone secretagogue receptor 1a
(GHSR1a) (5). In adults, ghrelin is predominantly produced
by gastric X/A-like cells, but also by many other organs such
as the kidney, the pituitary, the hypothalamus, the heart, the
placenta and immune cells (6). Despite its strong GH-
releasing activity, ghrelin also exhibits other prominent endo-
crine and nonendocrine actions (6). Ghrelin has been detected
in cord blood of human fetuses from 20 wk onwards (7).
During the antenatal period several organs can synthesize and
secrete ghrelin even before its presence in the stomach, which
only expresses ghrelin after 17 d post-conception (dpc) in rats
(8,9). Besides its presence in the placenta (10), antenatal
ghrelin expression has been documented in rat (since 15 dpc)
and human (since wk 10) pancreas (8,11) and in human fetal
lung as early as wk seven (12,13).
The developing lung seems to be a major source of ghrelin.
Significant ghrelin expression during the pseudoglandular
stage of human fetal lung development (7–18 wk of gestation)
was reported, suggesting that ghrelin might act as a regulator
of fetal lung development by autocrine/paracrine mechanisms
(13). In adult rats, it was recently demonstrated that ghrelin
modulates pulmonary vascular remodeling and hypertension
(14).
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The aforementioned reports led to the hypothesis that
ghrelin may be an important factor modulating lung develop-
ment in CDH. In the present study, ghrelin expression in
human and rat normal and hypoplastic fetal lungs was char-
acterized. Furthermore, the effect of exogenous administration
of ghrelin in a nitrofen-induced CDH rat model was tested.
Our findings show that ghrelin expression is augmented in
CDH and that exogenous administration of ghrelin is able to
partially attenuate pulmonary hypoplasia in CDH.
MATERIALS AND METHODS
Human fetal studies. Lung tissue was obtained from the archives of the
Department of Pathology, Erasmus MC, Rotterdam, following approval of the
experimental design and protocols by the institutional review committee.
Lung tissue was derived from 12 CDH patients including two samples
following termination of pregnancy. They were all treated postnatally with
standard protocols including immediate postnatal intubations, high frequency
oscillatory ventilation, vasopressive drugs if needed and inhaled NO. None of
the patients included in this study were subjected to extracorporeal membrane
oxygenation (ECMO) therapy (Table 1) as all died of therapy-resistant
respiratory insufficiency within minutes to hours after birth. As such, they
were considered very severe cases of pulmonary hypoplasia. As controls, 10
normal lungs between 13.5 and 39 wk of gestation, without pulmonary
abnormalities, were used. None of these patients received supplemental
oxygen or mechanical ventilation. All autopsies were performed within 24 h
of death according to the standard protocol designed by the Dutch Pediatric
Pathology Society. The specimens were fixed by immersion in 4% buffered
formalin, embedded in paraffin and processed for immunohistochemistry.
Immunohistochemistry (IHC). Immunostainings were performed on for-
malin-fixed and paraffin-embedded human tissues. Lung sections (5 m) were
placed on SuperFrost®Plus slides (Menzel-Glaser, Germany). The primary
antibodies were polyclonal rabbit antihuman ghrelin (H-031-30, Phoenix
Pharmaceuticals, CA) and polyclonal rabbit antihuman GHSR1a (Cys° amino
acids 330–366, H-001-62, Phoenix Pharmaceuticals, CA). After dewaxing in
xylene and rehydration in ethanol, the samples were incubated in 3% hydro-
gen peroxide in methanol to quench the endogenous peroxidase. Antigen
retrieval was achieved by boiling in 10 mM citrate buffer, followed by cooling
down to room temperature. Samples were blocked with 5% BSA (Roche,
Germany). Incubation with primary antibody occurred at 4°C overnight:
anti-ghrelin (1:3000) and anti-GHSR1a (1:500). Negative control reactions
consisted in omission of the primary antibody. Positive control reactions for
ghrelin in human stomach tissue and GHSR1a in human pituitary tissue were
performed. Incubation with the secondary antibody, goat anti-rabbit horse-
radish peroxidase conjugated serum (1:100) (P 0448, DAKO, Denmark), was
carried out at room temperature for 2 h. To visualize the peroxidase activities
in sections, diaminobenzidine tetrahydrochloride (Sigma–Aldrich Co.) was
used. Sections were counterstained with hematoxyline.
Morphometric analysis. Computer-assisted morphometric analysis was
performed using a StereoInvestigator program (MicroBrigthField, Williston,
VT). On each slide immunoreactive bronchi were identified and traced using
20 objective to calculate the epithelial bronchial area. Additionally, the
number of immunopositive cells on each bronchus was counted. Using these
data the proportion of ghrelin-expressing cells per epithelial bronchial area
was calculated.
Animal model and experimental design. Animal experiments were per-
formed accordingly to the Portuguese law for animal welfare. Animals were
housed in an accredited mouse house and treated as specified in the ‘Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health’ (National Institutes of Health Publication No.85-23,
revised 1996).
Sprague-Dawley female rats (225g, Charles-River, Barcelona) were main-
tained in appropriate cages under controlled conditions, fed with commercial
solid food and after mating they were checked for introital plugging. Forty
pregnant rats at day 9.5 of gestation randomly received by gavage either a
single-dose of 100 mg of 2,4-dichorophenyl-p-nitrophenylether (nitrofen)
dissolved in 1 mL of olive oil (n  28) or an equal volume of vehicle (n 
12). From both groups, rats were then randomly assigned to two different
protocols.
Protocol 1. From the control group, fetuses were removed by caesarian
section at 12.5, 15.5, 17.5, 19.5 and 21.5 dpc, whereas nitrofen-exposed
fetuses were removed at 17.5, 19.5 and 21.5 dpc since only after that
gestational age we could clearly distinguish the fetuses with or without CDH.
Fetuses with 12.5 and 15.5 dpc were processed in toto for hybridization
studies. In fetuses older than 15.5 dpc, the lungs were excised and the wet
weights of each lung were measured. Random left lung samples were
collected and processed for in situ hybridization. Samples used for the
quantification of ghrelin’s expression by real time-PCR were immersed in
RNAlater (Qiagen, Germany) and stored at 80°C.
This protocol resulted in three experimental groups: 1) control group, not
exposed to nitrofen nor ghrelin; 2) nitrofen group, nitrofen-exposed fetus
without diaphragmatic defect; 3) CDH group, nitrofen-exposed fetus with left
diaphragmatic defect.
Protocol 2. Nitrofen-exposed dams were randomly assigned to receive
ghrelin (100 g/Kg, BID, s.c.) or saline between 13.5 and 17.5 dpc. An active
fragment of ghrelin was obtained from the Peptides International, USA
(PGH-3628-PI, Human, Rat, 1–5), with functional assay activation at 10 nM
relative to ghrelin of 96  7%. Fetuses were removed at term (21.5 dpc) and
weighted. Organs that could be particularly affected in CDH (lung and heart)
were excised and weighted. Random left lung samples were collected and
processed for determination of total DNA and protein contents as previously
described (15).
This protocol resulted in six experimental groups: 1) control  saline
group, exposed neither to nitrofen nor ghrelin treated with saline; 2) nitrofen
 saline group, nitrofen-exposed fetus without diaphragmatic defect treated
with saline; 3) CDH  saline group, nitrofen-exposed fetus with left dia-
phragmatic defect treated with saline; 4) control  ghrelin group, not exposed
to nitrofen and treated with ghrelin; 5) nitrofen  ghrelin group, nitrofen-
exposed fetus without diaphragmatic defect treated with ghrelin; 6) CDH 
ghrelin group, nitrofen-exposed fetus with left diaphragmatic defect treated
with ghrelin.
In situ hybridization (ISH). Digoxigenin-labeled ghrelin probe was syn-
thesized from a 247bp fragment of prepro-ghrelin inserted in the pGEM-T
vector. The plasmid was linearized with NcoI and SP6 RNA polymerase was
used to synthesize the riboprobe. Tissue sections (10 m) were processed for
ISH as described by Strahle et al. (16).
PCR studies. Total mRNA from each sample was extracted using the
RNeasy Mini Kit Protect (Qiagen, Germany). Quantification of total mRNA
was done by spectrophotometry (BioPhotometer, Eppendorf, Germany). The
reverse transcription was carried out on a T-gradient thermocycler (Biometra,
Germany) using the kit Superscript II (Invitrogen, U.S.A) and 100 ng of
mRNA as template.
Quantitative PCR (qPCR). Total cDNA was used for the relative quanti-
fication by real time-PCR of ghrelin and of the reference gene -actin using
the LightCycler (Roche, Germany). All primers used were intron-spanning
(Table 2) and primer design was based on the available sequences in GenBank
(NCBI-NLM-PubMed-Gene). Real time-PCR reactions consisted in SYBR
Green PCR master mix (QuantiTech SYBRgreen PCR, Qiagen, Germany),
100 ng of cDNA and 10 pmol of each primer (Thermo Electron, Germany) in
a total volume of 20 L. Ghrelin amplification consisted of 15 min hot-start,
55 cycles (95°C 15 s, 58°C 25 s, 72°C 20 s) and acquisition mode at 80°C for
5 s. -actin amplification was performed with 15 min hot-start, 55 cycles
(95°C 15 s, 58°C 20 s, 72°C 15 s).
Ghrelin and -actin standard amplification curves (ST curves) were made
with randomly selected cDNA samples setting at r  0.99.
















1 18 161 0.012 Termination of
pregnancy
2 21 416 0.008 Termination of
pregnancy
3 34 1250 0.005 Minutes
4 36 2515 0.003 Several hours Pneumothorax
5 38 2870 0.005 30 minutes
6 38 1220 1 day
7 39 2890 0.003 15 minutes Pneumothorax
8 40 2050 0.006 During labor Trisomy 18
9 40 3510 0.006 Minutes
10 40 3225 0.005 6 hours
11 41 2765 0.006 1.5 hours
12 42 3355 0.002 30 minutes
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RT-PCR. For human material, 100 ng of the RT reaction was used for PCR
amplification, whereas for rat material, 300 ng were used. Standard amplifi-
cation conditions were used and the PCR reactions performed in an automatic
thermal cycler (MyCycler, BIO-RAD).
Statistic analysis. All quantitative data are presented as mean  SE. For
the results of real time-PCR, a one-way ANOVA on Ranks test was applied,
whereas for the evaluation of the effect on pulmonary hypoplasia of ghrelin’s
administration in control, nitrofen or CDH fetuses, a two-way ANOVA test
was performed. Upon statistically significant differences, a test of Student-
Newman-Keuls was selected to perform a pair–wise multiple comparisons.
Statistical significance was set at p  0.05.
RESULTS
Immunohistochemistry in normal and CDH human fetal
lungs. Immunohistochemistry studies showed that ghrelin-
producing cells were scattered at the level of the main bronchi
in all the studied cases during all the developmental stages. In
normal fetal lungs (Fig. 1A), ghrelin expression was predom-
inantly observed during the pseudoglandular and canalicular
stages of lung development. In CDH lungs, the production of
ghrelin was increased mainly in early stages of gestation
(Fig. 1B) as confirmed by morphometric analysis from avail-
able samples (Fig. 2).
Ghrelin expression pattern during normal and CDH pul-
monary development in rats. In situ hybridization experi-
ments (Fig. 3A) revealed that ghrelin was expressed in the
normal fetal lung during all the developmental stages studied
(12.5, 15.5, 17.5, 19.5 and 21.5 dpc). As shown in Fig. 3A, it
was clear that ghrelin mRNA was observed in primitive lung
epithelium with significant expression already at the earliest
stages of rat lung development (12.5 dpc). A maximum of
ghrelin expression was observed during the pseudoglandular
stage, and decreasing during subsequent stages of normal lung
development.
In nitrofen-exposed groups ghrelin mRNA was detected on
the pulmonary epithelium during all developmental stages
studied (Fig. 3B, 17.5, 19.5 and 21.5 dpc). Similarly, ghrelin
expression during CDH lung development decreased as ges-
tational time increased, being the pseudoglandular stage rep-
resentative of the maximum expression (Fig. 3B, 17.5 dpc). In
CDH lungs ghrelin expression appeared to be higher than in
age-matched control lungs (Figs. 3A,B). Since no significant
differences were observed between nitrofen and CDH groups,
pictures depicting ISH of lungs of CDH fetuses are the only
ones presented.
Quantitative PCR analysis. Real time-PCR experiments
were performed to quantify the expression of ghrelin observed
by ISH during normal and abnormal lung development
(Figs. 4 and 5). The mRNA levels of -actin were not
significantly altered during gestation in any of the studied
groups and were subsequently used to normalize the expres-
sion data for ghrelin. In the control group, ghrelin mRNA
levels were higher in the earliest gestational ages studied
(15.5 and 17.5 dpc) (Fig. 4). Ghrelin mRNA levels in nitrofen-
exposed fetuses were compared with those observed in the
control group at different gestational ages (Fig. 5). A pair-wise
analysis revealed that nitrofen and CDH groups presented
significantly higher levels of ghrelin mRNA than the control
group at 17.5 and 19.5 dpc, whereas at end-gestation
(21.5 dpc) ghrelin mRNA levels were appreciably higher in
CDH group than in the control and nitrofen groups (Fig. 5).
This data confirmed, therefore, the significant increase of
ghrelin expression in rat hypoplastic lungs, supporting the ISH
results.






hGhrelin AB029434 5-GTT CAG GAC ATC CTC TGG-3
5-GAG TCG TGG GAG TTG C-3
121
hGHSR1a U60179 5-TCA GGG ACC AGA ACC AC-3
5-GCC AGG CTC AAA GGA T-3
106
rGhrelin NM_021669 5-TTT CTC TGC TGG GCT TTC T-3
5-AGG CCA TGG TGT CTT CA-3
121
rGHSR1a NM_032075 5-CAG AAC CAC AAG CAG ACA
GTG-3
5-TGA TCT GAG CGA TCT CCA
GAG-3
136
r-actin NM_031144 5-GAT TTG GCA CCA CAC TTT
CTA CA-3
114
5-ACT TTG GTC ATC TTT TCA CGG
TTG G-3
Figure 1. Developmental production of ghrelin in normal and hypoplastic
(CDH) human lungs. A) Immunohistochemistry in normal human fetal lungs.
B) Immunohistochemistry in CDH human fetal lungs. Scale bar  50 m.
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Growth hormone secretagogue receptor expression in the
fetal lung. To clarify the mechanism of action of ghrelin,
GHSR1a expression was evaluated by RT-PCR in human and
rat material and by IHC in human material. GHSR1a mRNA
was not detected in human fetal lung (Fig. 6A). Corroborating
this data, and in contrast to human pituitary samples, IHC
studies also failed to detect GHSR1a in all human fetal lung
samples available. Several adult rat tissues such as pituitary,
lung, brain, stomach and heart, as well as control, nitrofen and
CDH fetal lungs from several gestational ages 17.5, 19.5,
21.5 dpc were tested (Fig. 6B). GHSR1a was only successfully
amplified in adult rat pituitary.
Effect of exogenous ghrelin administration. The previous
results suggested a role for ghrelin during lung development
as well as a potential modulating role in abnormal lung
development. This prompted the study of the effects of exog-
enous administration of ghrelin between 13.5 and 17.5 dpc
(Fig. 7). All nitrofen-exposed groups treated with ghrelin
presented an increase in lung-to-body weight ratio (Fig. 7).
Furthermore, ghrelin-induced growth appeared to be restricted
Figure 2. Results of morphometric analysis from Control () and CDH ()
human lungs.
Figure 3. Ghrelin expression pattern during the development of normal and
CDH rat lung. A) In situ hybridization in normal fetal lung. Scale bar (E12.5)
 25 m. Scale bar (E15.5)  500 m. Scale bar (E17.5, 19.5 and 21.5) 
100 m. B) In situ hybridization in hypoplastic CDH lung. Scale bar (E17.5,
19.5 and 21.5)  100 m.
Figure 4. Ghrelin mRNA expression levels during normal fetal rat lung
development, expressed in arbitrary units normalized for -actin, obtained by
real time-PCR (n  7 for all studied developmental ages). p  0.05:* versus
15.5dpc.
Figure 5. Ghrelin expression levels obtained by real time-PCR in nitrofen-
induced CDH rat model. Ghrelin mRNA levels expressed in arbitrary units
normalized for -actin at day 17.5 in control group fetuses (black bars, n 
7), nitrofen group fetuses (light grey bars, n  8) and CDH group fetuses
(dark grey bars, n  8). p  0.05: * verus Control group; § versus Nitrofen
group.
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to the lungs since heart-to-body weight ratio (Fig. 7) did
not change upon ghrelin administration. Total protein and
DNA content analyses supported the morphologic results. The
nitrofen  ghrelin group revealed increased total protein
(0.50  0.1 mg/g) and DNA content (17.3  1 g/g) when
compared with the nitrofen  saline group (0.42  0.1 mg/g
protein; 15.0  2 g/g DNA; p  0.05). Similar observations
were obtained for the CDH  ghrelin (0.35  0.2 mg/g
protein; 13.6  2 g/g DNA; p  0.05) and CDH  saline
groups (0.26  0.1 mg/g protein; 11.6  2 g/g DNA). No
significant statistical differences in the protein/DNA ratio
between the ghrelin-treated and nontreated groups were de-
tected.
DISCUSSION
The present study revealed that in normal fetal lungs ghrelin
was expressed in primitive epithelial cells as early as the
pseudoglandular stage of development with decreasing levels
of expression throughout gestation. Although a similar expres-
sion pattern was observed in hypoplastic lungs, ghrelin was
overexpressed in the CDH lungs from human and rat. Exog-
enous administration of ghrelin to nitrofen-treated dams led to
an attenuation of the CDH-related pulmonary hypoplasia. This
effect is mediated most likely through a GHSR1a-independent
pathway since GHSR1a was not detected in human and rat
fetal lungs.
Ghrelin expression was characterized in human and rat
normal and hypoplastic lungs. Human lung tissue was derived
from CDH patients with severe pulmonary hypoplasia, as well
as from the available controls. For rat studies, the nitrofen-
induced CDH model was used since it is the one that best
mimics the human disease (15,17,18). Nitrofen administration
leads to an equal interference in the growth of both lungs even
before the diaphragm development occurs. After the establish-
ment of the diaphragmatic defect, presumably from 16 dpc
onwards, ipsilateral lung development is impaired due to the
herniated abdominal organs (17).
In humans, the observations from Volante et al. (13) were
confirmed. Ghrelin positive cells appeared as isolated cells or
as small clusters in normal fetal epithelium (13). In normal
rat fetal lungs, ghrelin expression was observed as early as
12.5 dpc with ghrelin-positive cells appearing at the epithelial
level of the proximal bronchi. Furthermore, it was shown that
ghrelin expression levels decreased throughout gestation. Be-
sides the placenta (10), the developing lung and pancreas
express ghrelin earlier than other organs previously studied,
suggesting that branching organs are the main sources of
circulating fetal ghrelin. Although it is known that ghrelin
knock-out mice do not show significant lung abnormalities
(19), the early presence of ghrelin expressing cells, as well as
their prominent number in the fetal lung, may indicate a
developmental role for ghrelin.
In human or rat CDH-associated hypoplastic fetal lungs,
ghrelin expression remained restricted to the epithelium. The
number of ghrelin-positive cells per epithelial bronchial area
in human lung was increased mainly in early stages of lung
development suggesting overexpression of ghrelin in CDH
lungs. In experimental CDH rat lungs ghrelin mRNA levels
were significantly higher than in lungs of age-matched con-
trols. In humans, age-matched statistical comparisons could
not be performed due to the reduced number of available
samples representative of each fetal lung gestational stage.
During normal embryonic development ghrelin may be
acting via GH-dependent (endocrine) or independent (para-
crine) pathways. There are several reports suggesting that
GH-independent pathways, acting by autocrine/paracrine
mechanisms via GHSR1a, might be more relevant during
development than the GH-dependent pathways (13). How-
ever, GHSR1a was not detected in human or rat fetal lungs
rendering unlikely the hypothesis that ghrelin acts in fetal lung
through GHSR1a. Despite this evidence, the possibility that
ghrelin acts by autocrine/paracrine mechanisms via other re-
ceptor(s) than GHSR1a cannot be excluded, as it has been
suggested in other tissues (20,21). Nevertheless, the possibility of
involvement of GH-dependent endocrine pathways cannot be
ruled out. In fact, ghrelin expression in fetal lung reaches its peak
at mid-gestation, when serum GH levels also reach maximal
values (22). The presence of GH mRNA in the fetal rat lung
during pseudoglandular stage, was recently documented (23),
Figure 6. RT-PCR for GHSR. A) RT-PCR for GHSR1a in human material.
Ghrelin was used for checking RT-PCR for fetal lung sample. B) RT-PCR for
GHSR in adult rat material (Pituitary, Lung, Brain, Stomach and Heart) and
in fetal rat lung (Control, Nitrofen and CDH from gestational age 17.5, 19.5,
21.5 dpc). The reference gene used for checking RT-PCR was -actin.
Figure 7. Effect of ghrelin administration to nitrofen-treated dams between
13.5 and 17.5dpc. Organ-to-body weight ratio for all experimental groups was
determined. Control  saline (n  27); Control  ghrelin (n  13); Nitrofen
 saline (n  20); Nitrofen  ghrelin (n  24); CDH  saline (n  23);
CDH  ghrelin (n  34). p  0.05: * versus Nitrofen  saline group; § versus
CDH  saline group.
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and it has been suggested that fetal GH can interact with GH
receptors existent in fetal lung epithelium (24,25) and modulate
lung growth by interfering with IGF activity while increasing
IGFBP-2 (26). Ghrelin produced in the lung may represent one of
the major factors responsible for the mid-gestational peak of GH,
hence modulating fetal lung development.
Pulmonary hypoplasia associated with CDH may be inter-
preted as a consequence of the decrease in pulmonary growth
factors. However, this study reported a paradoxical increase in
ghrelin expression during abnormal CDH lung development.
There are two possible interpretations: i) it is a consequence of
lung immaturity or ii) it represents a compensatory response
of the hypoplastic lung attempting to recover to normal levels
of lung growth. Previous reports have also shown increased
levels of some growth factors in the CDH lung toward the end
of gestation (27–29). Most of these results were interpreted as
an indicator of lung immaturity in CDH based on the fact that
growth factor levels of hypoplastic lungs at end-gestation
were similar to the ones observed in normal fetal lung during
early-gestation (27,29). In this study, however, ghrelin levels
were always higher in the CDH groups than in age-matched
controls in all studied gestational ages. Consequently, ghrelin
overexpression in hypoplastic lungs does not seem to relate
with lung immaturity.
The observed ghrelin-positive cells in the lung have been
described as pulmonary neuroendocrine cells (PNEC) (13).
Neuroepithelial bodies (NEB) are clusters of innervated
PNEC (30) distributed throughout the airway mucosa. NEB
are the site of amines and peptides production (31) that seem
to have an important role during lung development as well as
during neonatal adaptation (32,33) acting as sensors (i.e.
hypoxia) (30,34,35). IJsselstijn et al. (32) described increased
expression in CDH infants of bombesin, a NEB-produced
molecule that regulates lung development (36). These authors
(37) also reported that the number of NEB per surface area of
lung parenchyma was increased at end-gestation in CDH
lungs in the CDH rat model, interpreting these findings as a
compensatory mechanism related to impaired lung develop-
ment. The aforementioned observations, as well as our own
data, prompt us to hypothesize that NEB could act as sensors
of lung growth. Under these circumstances, ghrelin should be
considered as a growth factor released in response to the
pulmonary hypoplasia associated with CDH.
The effect of exogenous ghrelin administration to normal
and nitrofen-exposed dams was tested. The gestational age
selected for ghrelin administration was based on the observed
maximal expression during the pseudoglandular stage. The
ghrelin dose was selected as previously defined for s.c. injec-
tion (14). Experimental observations indicated that in nitrofen-
exposed pups, ghrelin administration could normalize lung
growth in the nitrofen group and increase lung-to-body weight
ratio in the CDH group by 18%. The potential clinical rele-
vance of this effect should be emphasized, since such an
increase in lung parenchyma can be determinant in providing
a better adaptation of CDH fetus to extra-uterine life. Ghrelin
effect seemed lung-specific, since heart-to-body weight ratio
of the newborn pups was not altered. Interestingly, lung-to-
body weight ratio in normal fetus was not significantly
changed by ghrelin either. Therefore, ghrelin overexpression
in CDH should not be interpreted as a causative factor of lung
underdevelopment, but rather a consequence of lung hypopla-
sia, a countermeasure that elicits attenuation of lung underde-
velopment in CDH fetuses.
CONCLUSION
In conclusion, by analyzing human and rat fetuses, a peak
of ghrelin expression during the pseudoglandular stage of
normal lung development was reported. Ghrelin overexpres-
sion in hypoplastic lungs and the effect of ghrelin exogenous
administration to nitrofen-treated dams, suggests a role for
ghrelin in the mechanisms involved in attenuating CDH-
associated lung hypoplasia.
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